var data={"title":"Abemaciclib: Drug information","body":"<div id=\"topicContent\" class=\"utdArticleSection utdStyle\"><div id=\"drugTitle\">Abemaciclib: Drug information</div><div id=\"lexiTitleImg\"></div><div class=\"clear\"></div><div id=\"lcoSearchClickUrl\"><a href=\"http://online.lexi.com/lco/action/api/find/globalid/816001?utd=1\" target=\"_blank\">Access Lexicomp Online here.</a></div><div id=\"drugCopy\">Copyright 1978-2018 Lexicomp, Inc. All rights reserved.</div><div id=\"topicText\">(For additional information <a href=\"topic.htm?path=abemaciclib-patient-drug-information\" class=\"drug drug_patient\">see &quot;Abemaciclib: Patient drug information&quot;</a>)<br></br>For abbreviations and symbols that may be used in Lexicomp (<a href=\"image.htm?imageKey=DRUG%2F57469\" class=\"graphic graphic_table\">show table</a>)<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F50683018\" class=\"list ubnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: US</span>\n    <ul>\n      <li>Verzenio</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F50643795\" class=\"ex_sect_xr thclist drugH1Div drugBrandNames\"><span class=\"drugH1\">Pharmacologic Category</span>\n    <ul>\n      <li>\n        Antineoplastic Agent, Cyclin-Dependent Kinase Inhibitor</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F50685045\" class=\"block doa drugH1Div\"><span class=\"drugH1\">Dosing: Adult</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Breast cancer, HR-positive, HER2-negative (advanced or metastatic):</b> Oral:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Initial endocrine-based therapy in postmenopausal females:</i> 150 mg twice daily (in combination with an aromatase inhibitor); continue until disease progression or unacceptable toxicity (Goetz 2017)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Progressive disease following endocrine therapy and prior chemotherapy: </i>200 mg twice daily (as a single-agent); continue until disease progression or unacceptable toxicity (Dickler 2017)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Progressive disease on prior endocrine therapy:</i> 150 mg twice daily (in combination with fulvestrant [and a gonadotropin releasing hormone agonist if pre- or perimenopausal]); continue until disease progression or unacceptable toxicity (Sledge 2017)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <i>Missed/vomited doses:</i> If a dose is missed or vomited, take the next dose at the scheduled time.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Dosage adjustment for concomitant strong CYP3A inhibitor therapy:</b> Avoid concomitant use with the strong CYP3A inhibitor ketoconazole. With concurrent use of other strong CYP3A inhibitors, reduce the abemaciclib dose to 100 mg twice daily (if starting dose was 200 mg or 150 mg twice daily). For patients who have received a dose reduction to 100 mg twice daily due to toxicities, reduce the abemaciclib dose to 50 mg twice daily. If the strong CYP3A inhibitor is discontinued, allow 3 to 5 inhibitor half-lives to elapse and then increase abemaciclib dose to the dose used prior to initiating the strong CYP3A inhibitor.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F50685046\" class=\"block doe drugH1Div\"><span class=\"drugH1\">Dosing: Geriatric</span>\n    <p style=\"text-indent:0em;display:inline\">Refer to adult dosing.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F50685047\" class=\"block dor drugH1Div\"><span class=\"drugH1\">Dosing: Renal Impairment</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">CrCl &ge;30 mL/minute: No dosage adjustment necessary.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">CrCl &lt;30 mL/minute: There are no dosage adjustments provided in the manufacturer&rsquo;s labeling (has not been studied).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">ESRD: There are no dosage adjustments provided in the manufacturer&rsquo;s labeling (has not been studied).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F50685051\" class=\"block doh drugH1Div\"><span class=\"drugH1\">Dosing: Hepatic Impairment</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <i>Hepatic impairment at treatment initiation:</i></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Mild or moderate impairment (Child-Pugh class A or B): No dosage adjustment necessary.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Severe impairment (Child-Pugh class C): Reduce the abemaciclib frequency to once daily.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <i>Hepatotoxicity during treatment:</i></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Grade 1 (ALT, AST &gt;ULN to 3 times ULN): No abemaciclib dosage adjustment necessary.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Grade 2 (ALT, AST &gt;3 to 5 times ULN) <b>without</b> increase in total bilirubin &gt;2 times ULN: No abemaciclib dosage adjustment necessary.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Persistent or recurrent grade 2 or grade 3 (ALT, AST &gt;5 to 20 times ULN) <b>without</b> increase in total bilirubin &gt;2 times ULN: Withhold abemaciclib until toxicity resolves to baseline or grade 1, then resume at the next lower dose.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">AST and/or ALT &gt;3 times ULN <b>with</b> total bilirubin &gt;2 times ULN (in the absence of cholestasis): Discontinue abemaciclib treatment.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Grade 4 (ALT, AST &gt;20 times ULN): Discontinue abemaciclib treatment.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F50685743\" class=\"block dot drugH1Div\"><span class=\"drugH1\">Dosing: Adjustment for Toxicity</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Recommended abemaciclib dosage adjustments for adverse reactions:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Starting dose 200 mg twice a day (monotherapy):</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">First dose reduction: Reduce abemaciclib dose to 150 mg twice daily.</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Second dose reduction: Reduce abemaciclib dose to 100 mg twice daily.</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Third dose reduction: Reduce abemaciclib dose to 50 mg twice daily.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Starting dose 150 mg twice a day (in combination with an aromatase inhibitor or fulvestrant):</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">First dose reduction: Reduce abemaciclib dose to 100 mg twice daily.</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Second dose reduction: Reduce abemaciclib dose to 50 mg twice daily.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">If unable to tolerate 50 mg twice daily: Discontinue abemaciclib treatment.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;\">\n      <b>Hematologic toxicities:</b></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Note:</b> If blood cell growth factors are required, withhold abemaciclib dose for at least 48 hours after the last growth factor dose and until toxicity resolves to &le; grade 2; resume abemaciclib at the next lower dose (unless already reduced due to the toxicity that required the growth factor).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Grade 1 or 2: No abemaciclib dosage adjustment necessary.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Grade 3: Withhold abemaciclib until toxicity resolves to &le; grade 2 (no abemaciclib dosage reduction is necessary)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Grade 4 or recurrent grade 3: Withhold abemaciclib until toxicity resolves to &le; grade 2 and then resume abemaciclib at the next lower dose.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Non-hematologic toxicities:</b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Diarrhea: At the first sign of loose stools, begin management with antidiarrheal agents and increase oral fluid intake.</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Grade 1: No abemaciclib dosage adjustment necessary.</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Grade 2: If toxicity does not resolve to &le; grade 1 within 24 hours, withhold abemaciclib until resolution (no abemaciclib dosage reduction is necessary).</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Grade 2 that persists or recurs after resumption at the same dose (despite maximal supportive measures): Withhold abemaciclib until toxicity resolves to &le; grade 1 and then resume abemaciclib at the next lower dose.</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Grade 3 or 4 or requires hospitalization: Withhold abemaciclib until toxicity resolves to &le; grade 1 and then resume abemaciclib at the next lower dose.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Other toxicities (excluding diarrhea, hematologic toxicity or hepatotoxicity):</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Grade 1 or 2: No abemaciclib dosage adjustment necessary.</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Persistent or recurrent grade 2 toxicity that does not resolve to baseline or grade 1 within 7 days (despite maximal supportive measures): Withhold abemaciclib until toxicity resolves to baseline or to &le; grade 1 and then resume abemaciclib at the next lower dose.</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Grade 3 or 4: Withhold abemaciclib until toxicity resolves to baseline or to &le; grade 1 and then resume abemaciclib at the next lower dose.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F50683019\" class=\"block foc drugH1Div\"><span class=\"drugH1\">Dosage Forms</span>\n    <p style=\"text-indent:0em;text-align:justify;display:inline\">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Tablet, Oral: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Verzenio: 50 mg, 100 mg, 150 mg, 200 mg</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F50683017\" class=\"block geq drugH1Div\"><span class=\"drugH1\">Generic Equivalent Available (US)</span>\n    <p style=\"text-indent:0em;display:inline\">No</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F50643793\" class=\"block prod-avail drugH1Div\"><span class=\"drugH1\">Product Availability</span>\n    <p style=\"text-indent:0em;display:inline\">Verzenio: FDA approved September 2017; anticipated availability is currently undetermined</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F50684955\" class=\"block accres drugH1Div\"><span class=\"drugH1\">Prescribing and Access Restrictions</span>\n    <p style=\"text-indent:0em;display:inline\">Available through a specialty pharmacy distributor. Information regarding distribution is available from the manufacturer at 1-877-744-5675.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F50685788\" class=\"block adm drugH1Div\"><span class=\"drugH1\">Administration</span>\n    <p style=\"text-indent:0em;display:inline\">Oral: Administer at approximately the same times each day. May be administered with or without food. Swallow whole, do not crush, chew, or split tablets (do not ingest if tablets are broken, cracked, or not fully intact).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F50685002\" class=\"block hazard drugH1Div\"><span class=\"drugH1\">Hazardous Drugs Handling Considerations</span>\n    <p style=\"text-indent:0em;display:inline\">This medication is not on the NIOSH (2016) list; however, it may meet the criteria for a hazardous drug. Abemaciclib may cause teratogenicity or reproductive toxicity. Assess risk to determine appropriate containment strategy (USP-NF 2017).</p>\n    <p style=\"text-indent:0em;margin-top:2em;\">Use appropriate precautions for receiving, handling, administration, and disposal. Gloves (single) should be worn during receiving, unpacking, and placing in storage. NIOSH recommends single gloving for administration of intact tablets or capsules (NIOSH 2016).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F50643797\" class=\"block use drugH1Div\"><span class=\"drugH1\">Use</span>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>Breast cancer, advanced or metastatic:</b></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">As initial endocrine-based therapy (in combination with an aromatase inhibitor) for the treatment of hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced or metastatic breast cancer in postmenopausal women</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">In combination with fulvestrant for the treatment of HR-positive, HER2-negative advanced or metastatic breast cancer in women with disease progression following endocrine therapy</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">As monotherapy for the treatment of HR-positive, HER2-negative advanced or metastatic breast cancer in patients with disease progression following endocrine therapy and prior chemotherapy in the metastatic setting</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F50684952\" class=\"block mst drugH1Div\"><span class=\"drugH1\">Medication Safety Issues</span>\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Sound-alike/look-alike issues:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;\">Abemaciclib may be confused with acalabrutinib, afatinib, alectinib, axitinib, palbociclib, ribociclib</p></div>\r\n</div>\r\n\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">High alert medication:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;\">This medication is in a class the Institute for Safe Medication Practices (ISMP) includes among its lists of drug classes which have a heightened risk of causing significant patient harm when used in error.</p></div>\r\n</div>\r\n</div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F50667221\" class=\"block adr drugH1Div\"><span class=\"drugH1\">Adverse Reactions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">&gt;10%:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Central nervous system: Fatigue (65%), headache (20%), dizziness (11%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Dermatologic: Alopecia (12%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Endocrine &amp; metabolic: Weight loss (14%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Gastrointestinal: Diarrhea (90%), nausea (64%), decreased appetite (45%), abdominal pain (39%), vomiting (35%), constipation (17%), stomatitis (14%), xerostomia (14%), dysgeusia (12%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Hematologic &amp; oncologic: Anemia (25% to 68%; grade 3: 5%), decreased absolute lymphocyte count (42%; grade 3: 13%; grade 4: &lt;1%), neutropenia (37%; grade 3: 19%; grade 4: 5%), thrombocytopenia (20%; grade 3: 4%), leukopenia (17%, grade 3: 5%; grade 4: &lt;1%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Hepatic: Increased serum ALT (31%), increased serum AST (30%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Infection: Infection (31%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Neuromuscular &amp; skeletal: Arthralgia (15%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Renal: Increased serum creatinine (13% to 98%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Respiratory: Cough (19%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Miscellaneous: Fever (11%)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">1% to 10%:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Endocrine &amp; metabolic: Dehydration (10%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Hematologic &amp; oncologic: Febrile neutropenia (1%)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Frequency not defined:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Cardiovascular: Venous thromboembolism</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F50643798\" class=\"block coi drugH1Div\"><span class=\"drugH1\">Contraindications</span>\n    <p style=\"text-indent:0em;display:inline\">There are no contraindications listed in the manufacturer's labeling.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F50684994\" class=\"block war drugH1Div\"><span class=\"drugH1\">Warnings/Precautions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <i>\n        <b>Concerns related to adverse effects:</b></i></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Bone marrow suppression: Neutropenia commonly occurred in patients treated with abemaciclib, both as a single-agent and in combination with an aromatase inhibitor or fulvestrant. Grade 3 or higher neutropenia has been observed with both monotherapy and combination therapy. The median time to first episode of neutropenia (&ge; grade 3) was 29 to 33 days and the median duration of &ge; grade 3 neutropenia was 11 to 15 days. Anemia, leukopenia, and thrombocytopenia have also been observed. Monitor complete blood counts prior to treatment initiation, every 2 weeks for the first 2 months, then monthly for the next 2 months, and as clinically indicated. Grade 3 or 4 neutropenia may require treatment interruption, dose reduction, or treatment delay. Febrile neutropenia has occurred rarely, and deaths due to neutropenic sepsis have been observed (case reports).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Gastrointestinal toxicity: Diarrhea occurred in most patients treated with abemaciclib (either as monotherapy or when used in combination with an aromatase inhibitor or fulvestrant). Grade 3 diarrhea has occurred. Diarrhea had been associated with dehydration and infection. The incidence of diarrhea was higher during the initial month of abemaciclib; the median time to onset of the first diarrhea event was 6 to 8 days and the median duration of grade 2 and 3 diarrhea was 9 to 11 days and 6 to 8 days, respectively. Patients should initiate antidiarrheal medications (eg, loperamide) and increase oral fluid intake at the first sign of loose stools. Diarrhea may require treatment interruption and/or dose reduction. Nausea and vomiting (usually mild) may occur; stomatitis has also been reported.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Hepatotoxicity: Grade 3 or higher increases in ALT and AST have been reported with abemaciclib. The median time to onset of &ge; grade 3 ALT elevation was 57 to 61 days and the median time to resolution (to &lt; grade 3) was 14 days; the median time to onset of &ge; grade 3 AST elevation was 71 to 185 days and the median time to resolution was 13 to 15 days. Monitor liver function tests prior to treatment initiation, every 2 weeks for the first 2 months, then monthly for the next 2 months, and as clinically indicated. Hepatotoxicity may require treatment interruption, dose reduction, treatment delay, and/or discontinuation.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Thromboembolism: VTE events have been reported in patients treated with abemaciclib in combination with an aromatase inhibitor or fulvestrant. VTEs reported included deep vein thrombosis, pulmonary embolism, pelvic venous thrombosis, cerebral venous sinus thrombosis, subclavian and axillary vein thrombosis, and inferior vena cava thrombosis, some VTEs were fatal. Monitor for signs and symptoms of venous thrombosis and pulmonary embolism; manage as medically appropriate.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Disease-related concerns:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>\n        <i>&bull; </i></b>Hepatic impairment: Reduced initial doses are recommended for preexisting severe impairment (Child-Pugh class C).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <i>\n        <b>Concurrent drug therapy issues:</b></i></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Drug-drug interactions: Potentially significant interactions may exist, requiring dose or frequency adjustment, additional monitoring, and/or selection of alternative therapy. Consult drug interactions database for more detailed information.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F50666972\" class=\"block cyt drugH1Div\"><span class=\"drugH1\">Metabolism/Transport Effects</span>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>Substrate</b> of BCRP/ABCG2, CYP3A4 (major), P-glycoprotein/ABCB1; <b>Note:</b> Assignment of Major/Minor substrate status based on clinically relevant drug interaction potential; <b>Inhibits</b> BCRP/ABCG2, OCT2</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F50666969\" class=\"block dri drugH1Div\"><span class=\"drugH1\">Drug Interactions</span>\n    <br/><br/><div id=\"lexiInteractAddInfo\" class=\"lexi\">(For additional information: <a href=\"https://www.uptodate.com/drug-interactions/?search=&amp;topicId=115098&amp;source=responsive_topic\" class=\"dip\" target=\"_blank\">Launch drug interactions program</a>)</div><div id=\"lexiInteractImgB\" class=\"lexi\"><img src=\"/images/lexiComp/Lexicomp_2012_71x17.gif\" width=\"71\" height=\"17\" border=\"0\"/></div><div class=\"clear\"></div><p style=\"text-indent:-2em;margin-left:2em;\">Aprepitant: May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">BCG (Intravesical): Immunosuppressants may diminish the therapeutic effect of BCG (Intravesical). <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">BCG (Intravesical): Myelosuppressive Agents may diminish the therapeutic effect of BCG (Intravesical). <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Bosentan: May decrease the serum concentration of CYP3A4 Substrates (High risk with Inducers).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Ceritinib: May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors). Management: Use of ceritinib with a narrow therapeutic index CYP3A substrate (eg, alfentanil, cyclosporine, dihydroergotamine, ergotamine, fentanyl, pimozide, quinidine, sirolimus, tacrolimus) should be avoided when possible.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Chloramphenicol (Ophthalmic): May enhance the adverse/toxic effect of Myelosuppressive Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">CloZAPine: Myelosuppressive Agents may enhance the adverse/toxic effect of CloZAPine. Specifically, the risk for neutropenia may be increased. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Coccidioides immitis Skin Test: Immunosuppressants may diminish the diagnostic effect of Coccidioides immitis Skin Test. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Conivaptan: May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors).<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">CYP3A4 Inducers (Moderate): May decrease the serum concentration of CYP3A4 Substrates (High risk with Inducers).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">CYP3A4 Inducers (Strong): May decrease the serum concentration of Abemaciclib.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">CYP3A4 Inhibitors (Moderate): May increase the serum concentration of Abemaciclib.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">CYP3A4 Inhibitors (Strong): May increase the serum concentration of Abemaciclib. Management: In patients taking abemaciclib at a dose of 200 mg or 150 mg twice daily, reduce the dose to 100 mg twice daily when combined with strong CYP3A4 inhibitors. In patients taking abemaciclib 100 mg twice daily, decrease the dose to 50 mg twice daily.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Dabrafenib: May decrease the serum concentration of CYP3A4 Substrates (High risk with Inducers). Management: Seek alternatives to the CYP3A4 substrate when possible.  If concomitant therapy cannot be avoided, monitor clinical effects of the substrate closely (particularly therapeutic effects).<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Dasatinib: May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Deferasirox: May decrease the serum concentration of CYP3A4 Substrates (High risk with Inducers).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Deferiprone: Myelosuppressive Agents may enhance the neutropenic effect of Deferiprone. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Denosumab: May enhance the adverse/toxic effect of Immunosuppressants. Specifically, the risk for serious infections may be increased.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Dipyrone: May enhance the adverse/toxic effect of Myelosuppressive Agents. Specifically, the risk for agranulocytosis and pancytopenia may be increased<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Echinacea: May diminish the therapeutic effect of Immunosuppressants.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Fingolimod: Immunosuppressants may enhance the immunosuppressive effect of Fingolimod.  Management: Avoid the concomitant use of fingolimod and other immunosuppressants when possible. If combined, monitor patients closely for additive immunosuppressant effects (eg, infections).<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Fosaprepitant: May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Fusidic Acid (Systemic): May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors).<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Grapefruit Juice: May increase the serum concentration of Abemaciclib.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Idelalisib: May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors).<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Ketoconazole (Systemic): May increase the serum concentration of Abemaciclib.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Leflunomide: Immunosuppressants may enhance the adverse/toxic effect of Leflunomide. Specifically, the risk for hematologic toxicity such as pancytopenia, agranulocytosis, and/or thrombocytopenia may be increased.  Management: Consider not using a leflunomide loading dose in patients receiving other immunosuppressants.  Patients receiving both leflunomide and another immunosuppressant should be monitored for bone marrow suppression at least monthly.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">MetFORMIN: Abemaciclib may increase the serum concentration of MetFORMIN. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">MiFEPRIStone: May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors). Management: Minimize doses of CYP3A4 substrates, and monitor for increased concentrations/toxicity, during and 2 weeks following treatment with mifepristone. Avoid cyclosporine, dihydroergotamine, ergotamine, fentanyl, pimozide, quinidine, sirolimus, and tacrolimus.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Natalizumab: Immunosuppressants may enhance the adverse/toxic effect of Natalizumab. Specifically, the risk of concurrent infection may be increased. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Netupitant: May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Nivolumab: Immunosuppressants may diminish the therapeutic effect of Nivolumab. <i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Ocrelizumab: May enhance the immunosuppressive effect of Immunosuppressants.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Palbociclib: May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Pidotimod: Immunosuppressants may diminish the therapeutic effect of Pidotimod. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Pimecrolimus: May enhance the adverse/toxic effect of Immunosuppressants.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Pitolisant: May decrease the serum concentration of CYP3A4 Substrates (High risk with Inducers). Management: Combined use of pitolisant with a CYP3A4 substrate that has a narrow therapeutic index should be avoided. Other CYP3A4 substrates should be monitored more closely when used with pitolisant.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Promazine: May enhance the myelosuppressive effect of Myelosuppressive Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Roflumilast: May enhance the immunosuppressive effect of Immunosuppressants.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Sarilumab: May decrease the serum concentration of CYP3A4 Substrates (High risk with Inducers).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Siltuximab: May decrease the serum concentration of CYP3A4 Substrates (High risk with Inducers).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Simeprevir: May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Sipuleucel-T: Immunosuppressants may diminish the therapeutic effect of Sipuleucel-T. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">St John's Wort: May decrease the serum concentration of CYP3A4 Substrates (High risk with Inducers). Management: Consider an alternative for one of the interacting drugs. Some combinations may be specifically contraindicated. Consult appropriate manufacturer labeling.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Stiripentol: May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors). Management: Use of stiripentol with CYP3A4 substrates that are considered to have a narrow therapeutic index should be avoided due to the increased risk for adverse effects and toxicity.  Any CYP3A4 substrate used with stiripentol requires closer monitoring.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Tacrolimus (Topical): May enhance the adverse/toxic effect of Immunosuppressants.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Tertomotide: Immunosuppressants may diminish the therapeutic effect of Tertomotide. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Tocilizumab: May decrease the serum concentration of CYP3A4 Substrates (High risk with Inducers).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Tofacitinib: Immunosuppressants may enhance the immunosuppressive effect of Tofacitinib.  Management: Concurrent use with antirheumatic doses of methotrexate or nonbiologic disease modifying antirheumatic drugs (DMARDs) is permitted, and this warning seems particularly focused on more potent immunosuppressants.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Trastuzumab: May enhance the neutropenic effect of Immunosuppressants.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Vaccines (Inactivated): Immunosuppressants may diminish the therapeutic effect of Vaccines (Inactivated).  Management: Vaccine efficacy may be reduced. Complete all age-appropriate vaccinations at least 2 weeks prior to starting an immunosuppressant. If vaccinated during immunosuppressant therapy, revaccinate at least 3 months after immunosuppressant discontinuation.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Vaccines (Live): Immunosuppressants may enhance the adverse/toxic effect of Vaccines (Live). Immunosuppressants may diminish the therapeutic effect of Vaccines (Live).  Management: Avoid use of live organism vaccines with immunosuppressants; live-attenuated vaccines should not be given for at least 3 months after immunosuppressants.<i> Risk X: Avoid combination</i></p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F50685001\" class=\"block foi drugH1Div\"><span class=\"drugH1\">Food Interactions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Food: The AUC (of abemaciclib and active metabolites) is increased by 9% and the C<sub>max</sub> is increased by 26% with a high-fat, high-calorie meal (800 to 1,000 calories with 500 to 600 calories from fat).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Grapefruit: Coadministration with grapefruit may increase abemaciclib plasma concentrations. Management: Avoid concomitant administration with grapefruit and grapefruit products.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F50684991\" class=\"block pri drugH1Div\"><span class=\"drugH1\">Pregnancy Implications</span>\n    <p style=\"text-indent:0em;display:inline\">Based on the mechanism of action and data from animal reproduction studies, use during pregnancy may cause fetal harm. Pregnancy testing is recommended prior to treatment in females of reproductive potential. Women of reproductive potential should use effective contraception during therapy and for at least 3 weeks after the last abemaciclib dose. Abemaciclib may impair fertility in males of reproductive potential (based on findings in animal studies).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F50684992\" class=\"block brc drugH1Div\"><span class=\"drugH1\">Breast-Feeding Considerations</span>\n    <p style=\"text-indent:0em;display:inline\">It is not known if abemaciclib is present in breast milk. Due to the potential for adverse events in the breastfed infant, the manufacturer does not recommend breastfeeding during therapy and for at least 3 weeks after the last abemaciclib dose.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F50685752\" class=\"block dic drugH1Div\"><span class=\"drugH1\">Dietary Considerations</span>\n    <p style=\"text-indent:0em;display:inline\">Avoid grapefruit and grapefruit products. A high-fat, high-calorie meal (800 to 1,000 calories with 500 to 600 calories from fat) increases exposure.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F50685790\" class=\"block mop drugH1Div\"><span class=\"drugH1\">Monitoring Parameters</span>\n    <p style=\"text-indent:0em;display:inline\">CBC with differential and platelets (at baseline, every 2 weeks for the first 2 months, monthly for the next 2 months, then as clinically indicated); ALT, AST, and serum bilirubin (at baseline, every 2 weeks for the first 2 months, monthly for the next 2 months, then as clinically indicated); pregnancy testing (prior to treatment in females of reproductive potential). Signs/symptoms of diarrhea/dehydration and venous thrombosis and pulmonary embolism.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F50685029\" class=\"block pha drugH1Div\"><span class=\"drugH1\">Mechanism of Action</span>\n    <p style=\"text-indent:0em;display:inline\">Abemaciclib is a potent small molecule cyclin-dependent kinase (CDK) inhibitor which is selective for CDK 4 and 6; it blocks retinoblastoma tumor suppressor protein phosphorylation and prevents progression through the cell cycle, resulting in arrest at the G1 phase (Sledge 2017). Abemaciclib either alone or in combination with endocrine therapy has resulted in decreased tumor size.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F50685030\" class=\"block phk drugH1Div\"><span class=\"drugH1\">Pharmacodynamics/Kinetics</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Distribution: ~690.3 L; concentrations of abemaciclib and active metabolites M2 and M20 in CSF are comparable to unbound plasma concentrations</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Protein binding: Bound to plasma proteins, serum albumin, and alpha-1 acid glycoprotein: ~96% (abemaciclib); ~93% (M2 metabolite); ~97% (M18 metabolite); ~98% (M20 metabolite)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Metabolism: Primarily hepatic, via CYP3A4; forms primary metabolite N-desethylabemaciclib (M2; active), as well as additional metabolites including hydroxyabemaciclib (M20; active), hydroxy-N-desethylabemaciclib (M18; active), and an oxidative metabolite (M1).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Bioavailability: 45% (following a single 200 mg oral dose)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Half-life, elimination: 18.3 hours</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Time to peak: 8 hours (range: 4.1 to 24 hours)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Excretion: Feces (~81%; primarily as metabolites); Urine (~3%)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F50771513\" class=\"block fee drugH1Div\"><span class=\"drugH1\">Pricing: US</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Tablets</b> (Verzenio Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">50 mg (14): $3,284.40</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">100 mg (14): $3,284.40</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">150 mg (14): $3,284.40</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">200 mg (14): $3,284.40</p>\n    <p style=\"text-indent:0em;\">\n      <b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>\r\n</div><div id=\"topicAgreement\">Use of UpToDate is subject to the <a href=\"https://www.uptodate.com/legal/license\" class=\"licenseLink\" id=\"sla_in_page\">Subscription and License Agreement</a>.</div><div id=\"references\" class=\"headingAnchor\"><h1>REFERENCES</h1><ol id=\"reference\">\r\n<li>\r\n<div class=\"reference\">\n    &lt;800&gt; Hazardous Drugs&mdash;Handling in Healthcare Settings. <i>United States Pharmacopeia and National Formulary </i>(USP 40-NF 35). Rockville, MD: United States Pharmacopeia Convention; 2017:83-102.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Dickler MN, Tolaney SM, Rugo HS, et al. MONARCH 1, a phase II study of abemaciclib, a CDK4 and CDK6 inhibitor, as a single agent, in patients with refractory HR+/HER2- metastatic breast cancer. <i>Clin Cancer Res.</i> 2017;23(17):5218-5224. doi: 10.1158/1078-0432.CCR-17-0754.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/abemaciclib-drug-information/abstract-text/28533223/pubmed\" target=\"_blank\" id=\"28533223\">28533223</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Goetz MP, Toi M, Campone M, et al. MONARCH 3: Abemaciclib as initial therapy for advanced breast cancer. <i>J Clin Oncol</i>. 2017;35(32):3638-3646. doi: 10.1200/JCO.2017.75.6155.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/abemaciclib-drug-information/abstract-text/28968163/pubmed\" target=\"_blank\" id=\"28968163\">28968163</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Sledge GW Jr, Toi M, Neven P, et al. MONARCH 2: abemaciclib in combination with fulvestrant in women with HR+/HER2- advanced breast cancer who had progressed while receiving endocrine therapy. <i>J Clin Oncol.</i> 2017;35(25):2875-2884. doi: 10.1200/JCO.2017.73.7585.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/abemaciclib-drug-information/abstract-text/28580882/pubmed\" target=\"_blank\" id=\"28580882\">28580882</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    US Department of Health and Human Services; Centers for Disease Control and Prevention; National Institute for Occupational Safety and Health. NIOSH list of antineoplastic and other hazardous drugs in healthcare settings 2016. <a href=\"http://www.cdc.gov/niosh/topics/antineoplastic/pdf/hazardous-drugs-list_2016-161.pdf\" target=\"_blank\">http://www.cdc.gov/niosh/topics/antineoplastic/pdf/hazardous-drugs-list_2016-161.pdf</a>. Updated September 2016. Accessed October 5, 2017.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Verzenio (abemaciclib) [prescribing information]. Indianapolis, IN: Lilly USA, LLC; February 2018.</div>\r\n</li></ol></div><div id=\"topicVersionRevision\">Topic 115098 Version 15.0</div></div>","outline":"<div id=\"outlineSections\"><h2>Topic Outline</h2><ul><li class=\"plainItem\"><a sectionName=\"Brand Names: US\" href=\"#F50683018\" class=\"outlineLink\">Brand Names: US</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacologic Category\" href=\"#F50643795\" class=\"outlineLink\">Pharmacologic Category</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Adult\" href=\"#F50685045\" class=\"outlineLink\">Dosing: Adult</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Geriatric\" href=\"#F50685046\" class=\"outlineLink\">Dosing: Geriatric</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Renal Impairment\" href=\"#F50685047\" class=\"outlineLink\">Dosing: Renal Impairment</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Hepatic Impairment\" href=\"#F50685051\" class=\"outlineLink\">Dosing: Hepatic Impairment</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Adjustment for Toxicity\" href=\"#F50685743\" class=\"outlineLink\">Dosing: Adjustment for Toxicity</a></li><li class=\"plainItem\"><a sectionName=\"Dosage Forms\" href=\"#F50683019\" class=\"outlineLink\">Dosage Forms</a></li><li class=\"plainItem\"><a sectionName=\"Generic Equivalent Available (US)\" href=\"#F50683017\" class=\"outlineLink\">Generic Equivalent Available (US)</a></li><li class=\"plainItem\"><a sectionName=\"Product Availability\" href=\"#F50643793\" class=\"outlineLink\">Product Availability</a></li><li class=\"plainItem\"><a sectionName=\"Prescribing and Access Restrictions\" href=\"#F50684955\" class=\"outlineLink\">Prescribing and Access Restrictions</a></li><li class=\"plainItem\"><a sectionName=\"Administration\" href=\"#F50685788\" class=\"outlineLink\">Administration</a></li><li class=\"plainItem\"><a sectionName=\"Hazardous Drugs Handling Considerations\" href=\"#F50685002\" class=\"outlineLink\">Hazardous Drugs Handling Considerations</a></li><li class=\"plainItem\"><a sectionName=\"Use\" href=\"#F50643797\" class=\"outlineLink\">Use</a></li><li class=\"plainItem\"><a sectionName=\"Medication Safety Issues\" href=\"#F50684952\" class=\"outlineLink\">Medication Safety Issues</a></li><li class=\"plainItem\"><a sectionName=\"Adverse Reactions\" href=\"#F50667221\" class=\"outlineLink\">Adverse Reactions</a></li><li class=\"plainItem\"><a sectionName=\"Contraindications\" href=\"#F50643798\" class=\"outlineLink\">Contraindications</a></li><li class=\"plainItem\"><a sectionName=\"Warnings/Precautions\" href=\"#F50684994\" class=\"outlineLink\">Warnings/Precautions</a></li><li class=\"plainItem\"><a sectionName=\"Metabolism/Transport Effects\" href=\"#F50666972\" class=\"outlineLink\">Metabolism/Transport Effects</a></li><li class=\"plainItem\"><a sectionName=\"Drug Interactions\" href=\"#F50666969\" class=\"outlineLink\">Drug Interactions</a></li><li class=\"plainItem\"><a sectionName=\"Food Interactions\" href=\"#F50685001\" class=\"outlineLink\">Food Interactions</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Implications\" href=\"#F50684991\" class=\"outlineLink\">Pregnancy Implications</a></li><li class=\"plainItem\"><a sectionName=\"Breast-Feeding Considerations\" href=\"#F50684992\" class=\"outlineLink\">Breast-Feeding Considerations</a></li><li class=\"plainItem\"><a sectionName=\"Dietary Considerations\" href=\"#F50685752\" class=\"outlineLink\">Dietary Considerations</a></li><li class=\"plainItem\"><a sectionName=\"Monitoring Parameters\" href=\"#F50685790\" class=\"outlineLink\">Monitoring Parameters</a></li><li class=\"plainItem\"><a sectionName=\"Mechanism of Action\" href=\"#F50685029\" class=\"outlineLink\">Mechanism of Action</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacodynamics/Kinetics\" href=\"#F50685030\" class=\"outlineLink\">Pharmacodynamics/Kinetics</a></li><li class=\"plainItem\"><a sectionName=\"Pricing: US\" href=\"#F50771513\" class=\"outlineLink\">Pricing: US</a></li><li class=\"plainItem\"><a href=\"#references\">REFERENCES</a></li></ul></div><div><h2>GRAPHICS <a href=\"#\" id=\"viewAllGraphicsLink\">View All</a></h2><div id=\"outlineGraphics\"><ul><li><div id=\"DRUG_GEN/115098|TAB\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"TABLES\">TABLES</a></div><ul><li><a href=\"image.htm?imageKey=DRUG/57469\" class=\"graphic graphic_table\">- Lexicomp clinical abbreviations</a></li></ul></li></ul></div></div><div><h2>RELATED TOPICS</h2><div id=\"outlineTopics\"><ul><li><a href=\"topic.htm?path=abemaciclib-patient-drug-information\" class=\"drug drug_patient\">Abemaciclib: Patient drug information</a></li></ul></div></div>","javascript":null}